WeaveBio is developing BLSF — a bilayer silk fibroin scaffold designed to integrate, regenerate, and resorb. The platform is built to eliminate the need for autologous tissue harvest in urethral, bladder, and other hollow-organ reconstructive surgeries.
The Problem
For decades, reconstructive teams have rebuilt damaged hollow organs by harvesting tissue from elsewhere in the patient — buccal mucosa from the cheek, bowel from the intestine, skin from the thigh. The harvest works, but it doubles operative time, creates a second wound, drives donor-site morbidity, and produces outcomes that vary with surgeon experience and patient anatomy.
WeaveBio is building the alternative: an off-the-shelf, animal-free, engineered scaffold designed to deliver the same regenerative outcome — without taking anything from the patient.
Patients per year in the United States undergo a separate tissue-harvest surgery before reconstruction can begin.
Pipeline programs — from lead urethral stricture repair through bladder, urinary diversion, tracheal, and esophageal reconstruction.
One device, one off-the-shelf procedure. Replaces the harvest + reconstruction workflow with a single intraoperative step.
BLSF bilayer cross-section — impermeable outer film over porous inner film, integrating and resorbing as native tissue regenerates.
The Platform
BLSF is a fully synthetic, animal-free scaffold built from two engineered films of silk fibroin. The outer film is impermeable — a fluid barrier that supports epithelial regrowth. The inner film is porous — a substrate that guides cell ingrowth, tissue infiltration, and neovascularization. Together they form a tunable construct that integrates with native tissue, supports regeneration, and resorbs as the patient's own tissue takes over.
Because the architecture is engineered rather than borrowed, the same platform serves indications as different as urethra, bladder, and trachea. Porosity, mechanical properties, and resorption window are each tunable to match the regenerative biology of the target organ.
Off-the-shelf. Sterilizable. Animal-free. One manufacturing process. Multiple indications. Economies of scale designed in from the start.
The Pipeline
BLSF's tunability lets us address a broad set of hollow-organ reconstructive indications from a single platform. Our lead program targets urethral stricture — the indication with the clearest unmet need, the cleanest regulatory path, and the most mature preclinical package. Behind it, four additional programs extend the same platform into adjacent reconstructive markets.
| Program | Indication | Clinical Focus | Stage |
|---|---|---|---|
| WB-101 | Urethral stricture repair | Adult reconstructive urology | Pre-IDE / IDE-enabling |
| WB-102 | Hypospadias & pediatric urethral reconstruction | Pediatric urology | Preclinical |
| WB-103 | Bladder reconstruction / augmentation | Neurogenic bladder, oncology | Preclinical |
| WB-104 | Urinary diversion (conduit reconstruction) | Post-cystectomy reconstruction | Preclinical / research |
| WB-105 | Tracheal & esophageal reconstruction | Reconstructive otolaryngology | Research |
Preclinical proof-of-concept established across eight reconstructive indications. Programs above are prioritized by clinical urgency, regulatory clarity, and capital efficiency.
Team & Advisors
WeaveBio is led by an operating team with decades of combined experience across drug, device, and combination-product development — and advised by a bench drawn from leading programs in reconstructive urology, regenerative medicine, biomaterials, and reimbursement strategy.
Leadership
Advisory Board
"One platform. Three indications underway. A pipeline that extends across hollow-organ reconstruction."
Contact Us
For partnering, investor, clinical, or media inquiries, reach us directly by email. We typically respond within two business days.